Transaction · 0001231919-26-001136

Mpm Bioventures 2018, L.P.

MPM BIOVENTURES 2018, L.P., 10%, reported an open-market or private sale at Entrada Therapeutics, Inc. involving 38922.000000 shares for an estimated $280238.40. Reported holdings after the transaction were 4279426.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
TRDAEntrada Therapeutics, Inc.
Trade date
Aug 27, 2026
Filing date
Aug 31, 2026
View on SEC Insider profile
Estimated value-$280kShares × reported price
Shares traded38.9k$7.20 per share
Holdings after4.27MIndirect · See Footnote
% of reported position traded0.9%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 4,318,348 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TRDA price since this filing

Daily closing prices, with the filing date and available return windows
TRDA · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d +1.1%30d -9.9%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001231919-26-001136
Common Stock
Transaction date
Aug 27, 2026
Filed Aug 31, 2026, 10:26 PM · 4d delay
Shares
38,922 sh
$7.20 per share
Estimated value
-$280k
Computed from shares × price
Holdings after
4,279,426 sh
Indirect · See Footnote

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Repeat Seller
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
    Read the scoring methodology

    Signed filing-only points, not a probability or expected return. Version v1.

    Reported relationships & other filings

    Form 4 relationship flags and nearby filing context

    Reported roles

    No officer title

    Officer NoDirector No10% YesOther No
    Footnotes & amended
    1. F1

      The shares were sold as follows: 17,674 by MPM BioVentures 2014, L.P. ("BV 2014"), 1,179 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 608 by MPM Asset Management Investors BV2014 LLC ("AM BV2014")…

    2. 2018"), 964 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 358 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC")…

    3. partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2…

    4. manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

    5. F2

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

    6. (3 footnotes)

      number of shares sold at each separate price within the range set forth in this Form 4.

    7. F3

      The shares are held as follows: 1,943,217 by BV 2014, 129,609 by BV 2014(B), 66,886 by AM BV2014, 1,994,355 by BV 2018, 105,998 by BV 2018(B) and 39,361 by AM BV2018.

    8. F4

      Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

    9. F5

      The shares were sold as follows: 1,695 by BV 2014, 113 by BV 2014(B), 58 by AM BV2014, 1,740 by BV 2018, 93 by BV 2018(B) and 34 by AM BV2018.

    10. F6

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the…

    11. F7

      The shares are held as follows: 1,941,522 by BV 2014, 129,496 by BV 2014(B), 66,828 by AM BV2014, 1,992,615 by BV 2018, 105,905 by BV 2018(B) and 39,327 by AM BV2018.

    12. F8

      The shares were sold as follows: 20,097 by BV 2014, 1,341 by BV 2014(B), 692 by AM BV2014, 20,626 by BV 2018, 1,096 by BV 2018(B) and 407 by AM BV2018.

    13. F9

      Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of th…

    14. F10

      The shares are held as follows: 1,921,425 by BV 2014, 128,155 by BV 2014(B), 66,136 by AM BV2014, 1,971,989 by BV 2018, 104,809 by BV 2018(B) and 38,920 by AM BV2018.

    Original filing · 0001231919-26-001136
    Related transactions

    0 other transactions

    Same SEC filing
    Recent company activity

    0 recent txs

    TRDA